RxDoctor Payments Data

Christopher Hassett, DO

Neurology · Bellevue, OHNPI 1760825301

Payments from drug & device makers

$269,612in general payments, 2019–2025

Across 900 payments — averaging $299.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$109K
  • Sanofi$99K
  • Teva Pharmaceuticals USA, Inc.$31K
  • Bristol Myers Squibb$14K
  • UCB, Inc.$7K
  • AbbVie$4K
  • plus $7K from 36 others

What the payments were for

  • Consulting fees$37,01914%
  • Speaking & faculty fees$200,14974%
  • Travel & lodging$10,6864%
  • Food & beverage$21,3898%
  • Education$3690%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$269,612 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$187,760
Medicare patients
628
Services billed
3,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab20$197,889
Austedo XrDeutetrabenazine28$177,190
IngrezzaValbenazine Tosylate20$155,533
UbrelvyUbrogepant31$28,146
Glatiramer Acetate19$23,991
GlatopaGlatiramer Acetate13$20,241
Aimovig AutoinjectorErenumab-Aooe13$10,892
Emgality PenGalcanezumab-Gnlm12$9,726
Carbidopa-LevodopaCarbidopa/Levodopa355$8,272
Levetiracetam207$6,200
Memantine Hcl158$3,910
Gabapentin281$3,538
Divalproex Sodium ErDivalproex Sodium51$2,761
Pyridostigmine Bromide12$2,631
Pregabalin109$2,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$30,670$177,19028 claims
Neurocrine Biosciences, Inc.Ingrezza$20$155,53320 claims
AbbVieUbrelvy$3,736$28,14631 claims
Almatica Pharma LLCSertraline Hcl$12$47751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.

Other neurology in Bellevue

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →